Literature DB >> 34339014

EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.

Chien-Feng Li1,2,3, Ti-Chun Chan1,2, Cheng-Tang Pan4,5, Pichpisith Pierre Vejvisithsakul6,7, Jia-Chen Lai6, Szu-Yu Chen6, Ya-Wen Hsu6, Meng-Shin Shiao8, Yow-Ling Shiue9,10.   

Abstract

PURPOSE: Urinary bladder urothelial carcinoma (UBUC) is a common malignant disease, and its high recurrence rates impose a heavy clinical burden. The objective of this study was to identify signaling pathways downstream of epithelial membrane protein 2 (EMP2), which induces cytostasis and apoptosis in UBUC.
METHODS: A series of in vitro and in vivo assays using different UBUC-derived cell lines and mouse xenograft models were performed, respectively. In addition, primary UBUC specimens were evaluated by immunohistochemistry.
RESULTS: Exogenous expression of EMP2 in J82 UBUC cells significantly decreased DNA replication and altered the expression levels of several TGFβ signaling-related proteins. EMP2 knockdown in BFTC905 UBUC cells resulted in opposite effects. EMP2-dysregulated cell cycle progression was found to be mediated by the TGFβ/TGFBR1/SP1 family member SMAD. EMP2 or purinergic receptor P2X7 (P2RX7) gene expression upregulation induced apoptosis via both intrinsic and extrinsic pathways. In 242 UBUC patient samples, P2RX7 protein levels were found to be significantly and positively correlated with EMP2 protein levels. Low P2RX7 levels conferred poor disease-specific and metastasis-free survival rates, and significantly decreased apoptotic cell rates. EMP2 was found to physically interact with P2RX7. In the presence of a P2RX7 agonist, BzATP, overexpression of both EMP2 and P2RX7 significantly increased apoptotic cell rates compared to overexpression of EMP2 or P2RX7 alone.
CONCLUSIONS: EMP2 induces cytostasis via the TGFβ/SMAD/SP1 axis and recruits P2RX7 to enhance apoptosis in UBUC. Our data provide new insights that may be employed for the design of UBUC targeting therapies.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Apoptosis; Cyclin-dependent kinase inhibitor; Cytostasis; EMP2; P2RX7; Urinary bladder urothelial carcinoma

Mesh:

Substances:

Year:  2021        PMID: 34339014     DOI: 10.1007/s13402-021-00624-x

Source DB:  PubMed          Journal:  Cell Oncol (Dordr)        ISSN: 2211-3428            Impact factor:   6.730


  46 in total

1.  Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells.

Authors:  Li Tang; Yuesheng Zhang
Journal:  Mol Cancer Ther       Date:  2005-08       Impact factor: 6.261

2.  Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract.

Authors:  Yi-Wen Wang; Wei-Ming Li; Wen-Jeng Wu; Chee-Yin Chai; Tsuey-Yu Chang; Yin Sun; Chih-Jen Cheng; Yow-Ling Shiue; Shu-Jem Su; Hong-Lin Cheng; Hsiao-Sheng Liu; Nan-Haw Chow
Journal:  Am J Pathol       Date:  2013-07-06       Impact factor: 4.307

Review 3.  Targeting the TGFβ pathway for cancer therapy.

Authors:  Cindy Neuzillet; Annemilaï Tijeras-Raballand; Romain Cohen; Jérôme Cros; Sandrine Faivre; Eric Raymond; Armand de Gramont
Journal:  Pharmacol Ther       Date:  2014-11-06       Impact factor: 12.310

4.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland.

Authors:  P Lichtenstein; N V Holm; P K Verkasalo; A Iliadou; J Kaprio; M Koskenvuo; E Pukkala; A Skytthe; K Hemminki
Journal:  N Engl J Med       Date:  2000-07-13       Impact factor: 91.245

Review 5.  Prognostic value of cell-cycle regulation biomarkers in bladder cancer.

Authors:  Anirban P Mitra; Donna E Hansel; Richard J Cote
Journal:  Semin Oncol       Date:  2012-10       Impact factor: 4.929

6.  The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma.

Authors:  Chien-Feng Li; Wen-Jeng Wu; Wen-Ren Wu; Yu-Jing Liao; Lih-Ren Chen; Chun-Nung Huang; Ching-Chia Li; Wei-Ming Li; Hsuan-Ying Huang; Yi-Ling Chen; Shih-Shin Liang; Nan-Haw Chow; Yow-Ling Shiue
Journal:  Oncotarget       Date:  2015-04-20

Review 7.  Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.

Authors:  Z Ping Lin; Yong-Lian Zhu; Elena S Ratner
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

8.  Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis.

Authors:  Yejinpeng Wang; Liang Chen; Lingao Ju; Kaiyu Qian; Xuefeng Liu; Xinghuan Wang; Yu Xiao
Journal:  Front Oncol       Date:  2019-10-11       Impact factor: 6.244

Review 9.  Economic aspects of bladder cancer: what are the benefits and costs?

Authors:  K D Sievert; B Amend; U Nagele; D Schilling; J Bedke; M Horstmann; J Hennenlotter; S Kruck; A Stenzl
Journal:  World J Urol       Date:  2009-03-07       Impact factor: 4.226

10.  Role of genetic heterogeneity and epistasis in bladder cancer susceptibility and outcome: a learning classifier system approach.

Authors:  Ryan John Urbanowicz; Angeline S Andrew; Margaret Rita Karagas; Jason H Moore
Journal:  J Am Med Inform Assoc       Date:  2013-02-26       Impact factor: 4.497

View more
  1 in total

1.  Loss of EMP2 Inhibits Melanogenesis of MNT1 Melanoma Cells via Regulation of TRP-2.

Authors:  Enkhmend Enkhtaivan; Hyun Ji Kim; Boram Kim; Hyung Jung Byun; Lu Yu; Tuan Minh Nguyen; Thi Ha Nguyen; Phuong Anh Do; Eun Ji Kim; Kyung Sung Kim; Hiệu Phùng Huy; Mostafizur Rahman; Ji Yun Jang; Seung Bae Rho; Ho Lee; Gyeoung Jin Kang; Mi Kyung Park; Nan-Hyung Kim; Chang Ick Choi; Kyeong Lee; Hyo Kyung Han; Jungsook Cho; Ai Young Lee; Chang Hoon Lee
Journal:  Biomol Ther (Seoul)       Date:  2022-03-01       Impact factor: 4.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.